Loading company…
R1 Therapeutics develops treatments for kidney disease, including hyperphosphatemia linked to CKD.
R1 Therapeutics Ltd is based in San Francisco, US, and develops therapies for kidney disease. Its lead candidate, AP306, is a pan-phosphate transporter inhibitor under development for hyperphosphatemia associated with chronic kidney disease. In September 2026, the company raised USD 3 million in Series A funding from Samsara BioCapital, with Abingworth, F-Prime Capital, DaVita Venture Group, Curie.Bio, Symbiosis and U.S. Renal Care, Inc. participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in